Recently, Rugo et al. analyzed the antitumor activity of Pembrolizumab, an anti-PD-1 monoclonal antibody, in patients with ER+/Human Epidermal Growth Factor Receptor 2–negative advanced breast cancer (49). The gene discussed is ESR1; the disease is breast cancer.